Merck (MRK) initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Merck (MRK) initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC.

Merck's initiation of the Phase 3 KANDLELIT-007 trial for Calderasib, in combination with KEYTRUDA, is a significant step in advancing its oncology pipeline. This combination therapy could enhance treatment options for patients with advanced non-small cell lung cancer (NSCLC), potentially influencing the competitive landscape in cancer therapies and impacting Merck's valuation if positive results emerge.